Monopar Therapeutics (NASDAQ:MNPR) Reaches New 52-Week High – Should You Buy?

Monopar Therapeutics Inc. (NASDAQ:MNPR) shares hit a new 52-week high during trading on Thursday . The company traded as high as $105.62 and last traded at $108.2740, with a volume of 102678 shares trading hands. The stock had previously closed at $99.27.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. UBS Group set a $105.00 price objective on shares of Monopar Therapeutics in a report on Monday, June 29th. HC Wainwright restated a “buy” rating and set a $105.00 price target on shares of Monopar Therapeutics in a research report on Monday, June 29th. BTIG Research upped their price target on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Tuesday, April 21st. Finally, Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $108.75.

Monopar Therapeutics Price Performance

The stock has a market capitalization of $714.22 million, a P/E ratio of -56.10 and a beta of 1.46. The stock’s fifty day moving average is $71.07 and its two-hundred day moving average is $63.87.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.41. Analysts expect that Monopar Therapeutics Inc. will post -2.82 EPS for the current year.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP purchased a new position in Monopar Therapeutics in the 3rd quarter worth about $18,904,000. Siren L.L.C. acquired a new position in Monopar Therapeutics during the fourth quarter valued at $13,863,000. Deerfield Management Company L.P. purchased a new position in Monopar Therapeutics during the third quarter valued at approximately $13,048,000. RA Capital Management L.P. increased its stake in shares of Monopar Therapeutics by 30.5% in the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock worth $43,569,000 after acquiring an additional 156,000 shares during the last quarter. Finally, TCG Crossover Management LLC purchased a new stake in shares of Monopar Therapeutics during the third quarter worth $12,496,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.